At a glance
ClinicalIndex Comparison RecordPhase 3Unknown· 200 target
Drug / intervention
CD25 monoclonal antibody +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Mesenchymal Stem Cells Combined With CD25 Monoclonal Antibody and Calcineurin Inhibitors for Treatment of Steroid-resistant Acute Graft-versus-host Disease After Allogeneic Stem Cell Transplantation
Nanfang Hospital, Southern Medical University·interventional·Posted Sep 16, 2014·Updated Sep 16, 2014
In Brief
A Phase 3 clinical trial evaluating CD25 monoclonal antibody, calcineurin inhibitors, and 1 other intervention for Acute Graft-versus-host Disease. Targeting 200 participants across 1 site.
Detailed Summary
The purpose of this study is to compare the efficacy of CD25 monoclonal antibody and calcineurin inhibitors with or without mesenchymal stem cells (MSCs) in treating patients with steroid-resistant acute graft-versus-host disease (aGVHD) after allogeneic hematopoietic stem cell transplantation.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAcute Graft-versus-host Disease
CountriesChina
CollaboratorsGuangdong Provincial People's Hospital, Third Affiliated Hospital, Sun Yat-Sen University, Guangzhou General Hospital of Guangzhou Military Command, Guangzhou First People's Hospital, Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University, Southern Medical University, China, Peking University People's Hospital, Huazhong University of Science and Technology, Sun Yat-sen University, Academy Military Medical Science, China
Timeline
Phase 3UnknownOverdue
201520162017201820192020202120222023202420252026
Enrollment StartSep 2014
First PostedSep 2014
Primary CompletionSep 2018
Study CompletionDec 2018
TodayJul 2026
First PostedSep 16, 2014
Enrollment StartSep 1, 2014
Primary CompletionSep 1, 2018
Study CompletionDec 1, 2018
TodayJul 1, 2026
Enrollment to primary: 4 yearsPosted 11.8 years ago
Interventions
CD25 monoclonal antibodydrug
calcineurin inhibitorsdrug
MSCsbiological